EXACT Sciences (NASDAQ:EXAS) and Protalex (OTCMKTS:PRTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.
Insider and Institutional Ownership
91.3% of EXACT Sciences shares are owned by institutional investors. Comparatively, 0.2% of Protalex shares are owned by institutional investors. 3.2% of EXACT Sciences shares are owned by insiders. Comparatively, 80.0% of Protalex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
EXACT Sciences has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Protalex has a beta of -0.51, suggesting that its stock price is 151% less volatile than the S&P 500.
This is a summary of recent recommendations and price targets for EXACT Sciences and Protalex, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
EXACT Sciences presently has a consensus target price of $89.90, suggesting a potential upside of 0.71%. Given EXACT Sciences’ higher probable upside, equities analysts plainly believe EXACT Sciences is more favorable than Protalex.
This table compares EXACT Sciences and Protalex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares EXACT Sciences and Protalex’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|EXACT Sciences||$265.99 million||41.25||-$114.39 million||($0.99)||-90.17|
Protalex has lower revenue, but higher earnings than EXACT Sciences.
EXACT Sciences beats Protalex on 6 of the 10 factors compared between the two stocks.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Protalex Company Profile
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.